Skip to Content

Join the 'Hidradenitis Suppurativa' group to help and get support from people like you.

Hidradenitis Suppurativa News

FDA Approves Humira (adalimumab) for Moderate to Severe Hidradenitis Suppurativa

Posted 11 Sep 2015 by Drugs.com

NORTH CHICAGO, Ill., Sept. 10, 2015 /PRNewswire/ – AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Humira (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS). Humira is now the first and only FDA-approved therapy for adults with HS. Hidradenitis suppurativa is a chronic inflammatory skin disease characterized by inflamed, painful lesions typically located around the armpits and groin, on the buttocks and under the breasts.1-2 Earlier this year, the FDA granted Humira orphan drug designation for the treatment of moderate to severe HS (Hurley Stage II and Hurley Stage III disease), a population of fewer than 200,000 patients. The orphan drug designation provides Humira the potential to be granted seven years of market exclusivity for the treatment of moderate to severe HS. ... Read more

Related support groups: Humira, Hidradenitis Suppurativa, Humira Pen, Adalimumab

Ask a Question

Further Information

Related Condition Support Groups

Dermatological Disorders

Related Drug Support Groups

Humira, adalimumab